本帖最后由 老马 于 2012-1-13 21:20 编辑
' H {! q* E" C" q& @ L% X& y" N+ ~# w. o! d3 t% p) Y% F
爱必妥和阿瓦斯丁的比较
7 s3 {& _1 \% ^; b! X
$ o' R$ v r& b* P& X
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 m9 h$ }' I" L0 F( p! f) Q1 T! |* | c
" Q& k8 N( k4 U2 i( P' B
, y; q+ i$ U* h/ Vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' g( f4 o! f* R( i% d==================================================
u2 r* M. V$ E1 _. [% a- `# ]Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)- |' `; ?: r$ _; ]- r- S: I- D0 @
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 }# @& a3 P, \' U' b' l+ g# TResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* z) c7 P& k' P+ X( S: m2 R
|